High rates of azole-resistance and limited availability of pharmacological agents within the UK can make recurrent vulvovaginal candidiasis (RVVC) with Candida glabrata a challenging infection to treat. In this report, we describe our experience in managing C. glabrata RVVC and present the case of a patient with poor response to therapy and a protracted treatment course, spanning almost 4 years. We also highlight the need for evidence-based management protocols that consider the national availability of alternative treatments.
Journal article
2022-09-01T00:00:00+00:00
33
939 - 942
3
Antifungal, treatment, women, Azoles, Candida glabrata, Candidiasis, Vulvovaginal, Female, Humans, Recurrence